reports
Stereotaxis Announces Definitive Agreement to Acquire Access Point Tec...
Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologies EP (APT), a privately-held Minnesota-based developer of innovative electrophysiology catheters. “Acquiring APT provides Stereotaxis with high-quality catheter development and manufacturing capabilities, and will am...
Journey Medical Corporation Reports First Quarter 2024 Financial Resul...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., May 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journ...
Dundee Corporation Declares Quarterly First Preference Shares, Series ...
Dundee Corporation Declares Quarterly First Preference Shares, Series 2 Dividend TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.PR.B) (“Dundee”) announced today that its board of directors has approved the payment of a quarterly cash dividend of $0.33025 per cumulative 5-year rate reset first preference share, series 2 payable on July 2, 2024 to shareholders of record on June 18, 2024. The dividend is designated as an eligible dividend for the purposes of section 89 of the Income Tax Act (Canada). ABOUT DUNDEE CORPORATION Dundee Corporation is a public Canadian i...
Dundee Corporation Declares Quarterly First Preference Shares, Series ...
Dundee Corporation Declares Quarterly First Preference Shares, Series 3 Dividend TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.PR.D) (“Dundee”) announced today that its board of directors has approved the payment of a quarterly cash dividend of $0.56595 per cumulative floating rate first preference share, series 3 payable on July 2, 2024 to shareholders of record on June 18, 2024. The dividend is designated as an eligible dividend for the purposes of section 89 of the Income Tax Act (Canada). ABOUT DUNDEE CORPORATION Dundee Corporation is a public Canadian indep...
Voyager Therapeutics Reports First Quarter 2024 Financial and Operatin...
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results - Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks - - Development candidates selected for Neurocrine-partnered GBA1 and Friedreich’s Ataxia gene therapy programs; potential for three gene therapies, including SOD1-ALS, to enter the clinic in 2025 - - Appointed neurology clinical development expert Toby Ferguson, M.D., Ph.D., as Chief Medical Officer - - Strong cash ...
Cara Therapeutics Reports First Quarter 2024 Financial Results
Cara Therapeutics Reports First Quarter 2024 Financial Results Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. “Our notalgia paresthetica (NP) pivotal clini...
Vaxart Provides Business Update and Reports First Quarter 2024 Financi...
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator as early as the second quarter of 2024 Anticipates meeting with the FDA in mid-2024 to evaluate clinical data and discuss next steps for its norovirus program Conference call today at ...
Allogene Therapeutics Reports First Quarter 2024 Financial Results and...
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Billion in the US to More Than $9.5 Billion in the Combined U.S., EU Member States and the United KingdomC...
AVITA Medical Reports First Quarter Financial Results
AVITA Medical Reports First Quarter Financial Results VALENCIA, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the first quarter ended March 31, 2024. Financial Results and Recent Business Updates Commercial revenue increased approximately 5.8% to $11.1 million compared to the same period in 2023Gross profit margin of 86.4%Launched PermeaDerm, a co-branded biosynthet...
Teknova Reports First Quarter 2024 Financial Results
Teknova Reports First Quarter 2024 Financial Results First quarter 2024 total revenue was $9.3 million, up 2% from prior yearLaunch of Build-Tek™ Custom ConfiguratorCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2024. “I am pleased with our p...
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healt...
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that management will attend the 2024 RBC Capital Markets Global Healthcare Conference that will take place May 14-15, 2024 in New York, NY. Details are as follows: 2024 RBC Capital Markets Global Healthcare ConferenceDate:May 14-15, 2024Location:New York, NY Management ...
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect In...
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is scheduled to present in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024 at 3:00 p.m. ET in New York, NY. In addition to the fireside chat, the management team will host investor meetings at ...
Assure & Danam to Host Corporate Update Call & Webcast
Assure & Danam to Host Corporate Update Call & Webcast DENVER, May 13, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced today that management will host a joint corporate update call with Danam on Thursday, May 16, 2024 at 4:00 PM Eastern Time to provide a corporate update. Conference Call InformationDate: Thursday, May 16, 2024Time: 4:00 PM Eastern TimeToll Free: 877-545-0523International: 973-528-0016Participant Access Code: 229289Webcast Link: C...
MYR Group Inc. to Attend Wells Fargo Industrials Investor Conference i...
MYR Group Inc. to Attend Wells Fargo Industrials Investor Conference in June THORNTON, Colo., May 13, 2024 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United States and Canada, announced it will attend the 2024 Wells Fargo Industrials Conference. MYR Group’s Chief Executive Officer, Rick Swartz, and Chief Financial Officer, Kelly Huntington, will meet with institutional investors during the Wells Fargo Industrials invest...
- ABGSC Renewable Energy Research
- Olof Cederholm
The Philadelphia Inquirer Names AIR Communities a 2024 Top Workplace
PHILADELPHIA--(BUSINESS WIRE)-- Apartment Income REIT Corp. (“AIR” or “AIR Communities”) (NYSE: AIRC) announced today that it has been named a Top Workplace in Philadelphia by The Philadelphia Inquirer. The annual list of Top Workplaces is administered by Energage and based solely on anonymous employee feedback that measures several aspects of workplace culture, including alignment, execution, and engagement. This press release features multimedia. View the full release here: Apartment Income REIT Corp. (“AIR” or “AIR Communities”) (NYSE: AIRC) announced today that it has been named a Top Wor...
Akoya Biosciences Reports First Quarter 2024 Financial Results
Akoya Biosciences Reports First Quarter 2024 Financial Results MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. Business Highlights Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase.Akoya the establishment of a new Manufacturing Center of Excellence in Marlborough, Massachusetts to scal...
Fractyl Health Reports First Quarter 2024 Financial Results and Provid...
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1 pivotal study in patients with inadequately controlled T2D anticipated in the fourth quarter 2024 Update from real-world Germany registry study of Revita in patients with T2D at DDG Annual Meeting Appointed Adrian Kimber as Chief Commercial Officer to lead Revita launch readiness activities Conference call ...
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annua...
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET. The live webcast may be accessed under the Investors tab on and will be archived fo...
- Thomas J. Schiessle
Inventory reduction in China completed - guidance FY24 confirmed - gro...
Costs are under control, but an increase in sales in H2/FY 24 is necessary to achieve the bottom line of guidance FY24, which is now qualified as "ambitious". Once there is more clarity on this, the guidance will be specified. The guidance FY24will now only be raised by the D.O.R.C. top-line contribution (FY24: approx. € 100m; D.O.R.C. bottom-line contributions (incl. ppa) will follow later).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.